LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is leading efforts in addressing some of the pressing challenges in cancer treatment. “Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target,” reads a recent article. “LIXTE’s platform is built on its proprietary LB-100 compound, a one-of-a-kind inhibitor of Protein Phosphatase 2A (‘PP2A’). PP2A is a critical enzyme involved in various cellular processes, including cell growth regulation, DNA repair, and modulation of the immune response. Through the selective inhibition of PP2A, LB-100 is strategically designed to make cancer cells more treatable while also boosting the body’s immunity to tumors… This strategic approach is important because resistance and limited efficacy are major impediments in oncology. Different cancers fail to respond adequately to immunotherapy. The company’s strategy is not aimed at replacing these therapies, but rather at improving them, making it possible for standard treatments to work for more patients.”
To view the full article, visit https://ibn.fm/25rlt
About LIXTE Biotechnology Holdings Inc.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com ), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for ovarian clear cell carcinoma and metastatic colon cancer.
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN